 | • レポートコード：MRC2-11QY11619 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はうつ病性障害のグローバル市場について調査・分析したレポートです。種類別（三環系抗うつ薬、選択的セロトニン再取り込み阻害薬、セロトニン-ノルエピネフリン再取り込み阻害薬、モノアミン酸化酵素阻害薬、セロトニン拮抗薬・再取り込み阻害薬、その他）市場規模、用途別（病院、外来手術センター、診断センター、在宅医療施設、介護センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別うつ病性障害の競争状況、市場シェア ・世界のうつ病性障害市場：種類別市場規模 2015年-2020年（三環系抗うつ薬、選択的セロトニン再取り込み阻害薬、セロトニン-ノルエピネフリン再取り込み阻害薬、モノアミン酸化酵素阻害薬、セロトニン拮抗薬・再取り込み阻害薬、その他） ・世界のうつ病性障害市場：種類別市場規模予測 2021年-2026年（三環系抗うつ薬、選択的セロトニン再取り込み阻害薬、セロトニン-ノルエピネフリン再取り込み阻害薬、モノアミン酸化酵素阻害薬、セロトニン拮抗薬・再取り込み阻害薬、その他） ・世界のうつ病性障害市場：用途別市場規模 2015年-2020年（病院、外来手術センター、診断センター、在宅医療施設、介護センター） ・世界のうつ病性障害市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター、診断センター、在宅医療施設、介護センター） ・北米のうつ病性障害市場分析：米国、カナダ ・ヨーロッパのうつ病性障害市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのうつ病性障害市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のうつ病性障害市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのうつ病性障害市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alkermes、Allergan、Bristol Myers Squibb、Eli Lilly、Glaxosmithkline、H. Lundbeck、Merck、Pfizer、Teva Pharmaceutical、Takeda Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression.
The Depressive Disorder market will undergo a period of steady growth from 2015 to 2025, mainly attributed to the growth in atypical antipsychotics and the expected launch of five pipeline.
Market Analysis and Insights: Global Depressive Disorder Market
The global Depressive Disorder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Depressive Disorder Scope and Market Size
Depressive Disorder market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Depressive Disorder market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Alkermes
Allergan
Bristol Myers Squibb
Eli Lilly
Glaxosmithkline
H. Lundbeck
Merck
Pfizer
Teva Pharmaceutical
Takeda Pharmaceutical
Market segment by Type, the product can be split into
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist And Reuptake Inhibitors
Others
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Homecare Settings
Long Term Care Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Depressive Disorder Revenue
1.4 Market by Type
1.4.1 Global Depressive Disorder Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tricyclic Antidepressants
1.4.3 Selective Serotonin Reuptake Inhibitors
1.4.4 Serotonin-Norepinephrine Reuptake Inhibitors
1.4.5 Monoamine Oxidase Inhibitors
1.4.6 Serotonin Antagonist And Reuptake Inhibitors
1.4.7 Others
1.5 Market by Application
1.5.1 Global Depressive Disorder Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Diagnostic Centers
1.5.5 Homecare Settings
1.5.6 Long Term Care Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Depressive Disorder Market Perspective (2015-2026)
2.2 Global Depressive Disorder Growth Trends by Regions
2.2.1 Depressive Disorder Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Depressive Disorder Historic Market Share by Regions (2015-2020)
2.2.3 Depressive Disorder Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Depressive Disorder Market Growth Strategy
2.3.6 Primary Interviews with Key Depressive Disorder Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Depressive Disorder Players by Market Size
3.1.1 Global Top Depressive Disorder Players by Revenue (2015-2020)
3.1.2 Global Depressive Disorder Revenue Market Share by Players (2015-2020)
3.1.3 Global Depressive Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Depressive Disorder Market Concentration Ratio
3.2.1 Global Depressive Disorder Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Depressive Disorder Revenue in 2019
3.3 Depressive Disorder Key Players Head office and Area Served
3.4 Key Players Depressive Disorder Product Solution and Service
3.5 Date of Enter into Depressive Disorder Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Depressive Disorder Historic Market Size by Type (2015-2020)
4.2 Global Depressive Disorder Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Depressive Disorder Market Size by Application (2015-2020)
5.2 Global Depressive Disorder Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Depressive Disorder Market Size (2015-2020)
6.2 Depressive Disorder Key Players in North America (2019-2020)
6.3 North America Depressive Disorder Market Size by Type (2015-2020)
6.4 North America Depressive Disorder Market Size by Application (2015-2020)
7 Europe
7.1 Europe Depressive Disorder Market Size (2015-2020)
7.2 Depressive Disorder Key Players in Europe (2019-2020)
7.3 Europe Depressive Disorder Market Size by Type (2015-2020)
7.4 Europe Depressive Disorder Market Size by Application (2015-2020)
8 China
8.1 China Depressive Disorder Market Size (2015-2020)
8.2 Depressive Disorder Key Players in China (2019-2020)
8.3 China Depressive Disorder Market Size by Type (2015-2020)
8.4 China Depressive Disorder Market Size by Application (2015-2020)
9 Japan
9.1 Japan Depressive Disorder Market Size (2015-2020)
9.2 Depressive Disorder Key Players in Japan (2019-2020)
9.3 Japan Depressive Disorder Market Size by Type (2015-2020)
9.4 Japan Depressive Disorder Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Depressive Disorder Market Size (2015-2020)
10.2 Depressive Disorder Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Depressive Disorder Market Size by Type (2015-2020)
10.4 Southeast Asia Depressive Disorder Market Size by Application (2015-2020)
11 India
11.1 India Depressive Disorder Market Size (2015-2020)
11.2 Depressive Disorder Key Players in India (2019-2020)
11.3 India Depressive Disorder Market Size by Type (2015-2020)
11.4 India Depressive Disorder Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Depressive Disorder Market Size (2015-2020)
12.2 Depressive Disorder Key Players in Central & South America (2019-2020)
12.3 Central & South America Depressive Disorder Market Size by Type (2015-2020)
12.4 Central & South America Depressive Disorder Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alkermes
13.1.1 Alkermes Company Details
13.1.2 Alkermes Business Overview
13.1.3 Alkermes Depressive Disorder Introduction
13.1.4 Alkermes Revenue in Depressive Disorder Business (2015-2020))
13.1.5 Alkermes Recent Development
13.2 Allergan
13.2.1 Allergan Company Details
13.2.2 Allergan Business Overview
13.2.3 Allergan Depressive Disorder Introduction
13.2.4 Allergan Revenue in Depressive Disorder Business (2015-2020)
13.2.5 Allergan Recent Development
13.3 Bristol Myers Squibb
13.3.1 Bristol Myers Squibb Company Details
13.3.2 Bristol Myers Squibb Business Overview
13.3.3 Bristol Myers Squibb Depressive Disorder Introduction
13.3.4 Bristol Myers Squibb Revenue in Depressive Disorder Business (2015-2020)
13.3.5 Bristol Myers Squibb Recent Development
13.4 Eli Lilly
13.4.1 Eli Lilly Company Details
13.4.2 Eli Lilly Business Overview
13.4.3 Eli Lilly Depressive Disorder Introduction
13.4.4 Eli Lilly Revenue in Depressive Disorder Business (2015-2020)
13.4.5 Eli Lilly Recent Development
13.5 Glaxosmithkline
13.5.1 Glaxosmithkline Company Details
13.5.2 Glaxosmithkline Business Overview
13.5.3 Glaxosmithkline Depressive Disorder Introduction
13.5.4 Glaxosmithkline Revenue in Depressive Disorder Business (2015-2020)
13.5.5 Glaxosmithkline Recent Development
13.6 H. Lundbeck
13.6.1 H. Lundbeck Company Details
13.6.2 H. Lundbeck Business Overview
13.6.3 H. Lundbeck Depressive Disorder Introduction
13.6.4 H. Lundbeck Revenue in Depressive Disorder Business (2015-2020)
13.6.5 H. Lundbeck Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Depressive Disorder Introduction
13.7.4 Merck Revenue in Depressive Disorder Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Depressive Disorder Introduction
13.8.4 Pfizer Revenue in Depressive Disorder Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Details
13.9.2 Teva Pharmaceutical Business Overview
13.9.3 Teva Pharmaceutical Depressive Disorder Introduction
13.9.4 Teva Pharmaceutical Revenue in Depressive Disorder Business (2015-2020)
13.9.5 Teva Pharmaceutical Recent Development
13.10 Takeda Pharmaceutical
13.10.1 Takeda Pharmaceutical Company Details
13.10.2 Takeda Pharmaceutical Business Overview
13.10.3 Takeda Pharmaceutical Depressive Disorder Introduction
13.10.4 Takeda Pharmaceutical Revenue in Depressive Disorder Business (2015-2020)
13.10.5 Takeda Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Depressive Disorder Key Market Segments
Table 2. Key Players Covered: Ranking by Depressive Disorder Revenue
Table 3. Ranking of Global Top Depressive Disorder Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Depressive Disorder Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tricyclic Antidepressants
Table 6. Key Players of Selective Serotonin Reuptake Inhibitors
Table 7. Key Players of Serotonin-Norepinephrine Reuptake Inhibitors
Table 8. Key Players of Monoamine Oxidase Inhibitors
Table 9. Key Players of Serotonin Antagonist And Reuptake Inhibitors
Table 10. Key Players of Others
Table 11. Global Depressive Disorder Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Depressive Disorder Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Depressive Disorder Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Depressive Disorder Market Share by Regions (2015-2020)
Table 15. Global Depressive Disorder Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Depressive Disorder Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Depressive Disorder Market Growth Strategy
Table 21. Main Points Interviewed from Key Depressive Disorder Players
Table 22. Global Depressive Disorder Revenue by Players (2015-2020) (Million US$)
Table 23. Global Depressive Disorder Market Share by Players (2015-2020)
Table 24. Global Top Depressive Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Depressive Disorder as of 2019)
Table 25. Global Depressive Disorder by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Depressive Disorder Product Solution and Service
Table 28. Date of Enter into Depressive Disorder Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 31. Global Depressive Disorder Market Size Share by Type (2015-2020)
Table 32. Global Depressive Disorder Revenue Market Share by Type (2021-2026)
Table 33. Global Depressive Disorder Market Size Share by Application (2015-2020)
Table 34. Global Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 35. Global Depressive Disorder Market Size Share by Application (2021-2026)
Table 36. North America Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Depressive Disorder Market Share (2019-2020)
Table 38. North America Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 39. North America Depressive Disorder Market Share by Type (2015-2020)
Table 40. North America Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 41. North America Depressive Disorder Market Share by Application (2015-2020)
Table 42. Europe Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Depressive Disorder Market Share (2019-2020)
Table 44. Europe Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Depressive Disorder Market Share by Type (2015-2020)
Table 46. Europe Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Depressive Disorder Market Share by Application (2015-2020)
Table 48. China Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 49. China Key Players Depressive Disorder Market Share (2019-2020)
Table 50. China Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 51. China Depressive Disorder Market Share by Type (2015-2020)
Table 52. China Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 53. China Depressive Disorder Market Share by Application (2015-2020)
Table 54. Japan Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Depressive Disorder Market Share (2019-2020)
Table 56. Japan Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Depressive Disorder Market Share by Type (2015-2020)
Table 58. Japan Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Depressive Disorder Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Depressive Disorder Market Share (2019-2020)
Table 62. Southeast Asia Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Depressive Disorder Market Share by Type (2015-2020)
Table 64. Southeast Asia Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Depressive Disorder Market Share by Application (2015-2020)
Table 66. India Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 67. India Key Players Depressive Disorder Market Share (2019-2020)
Table 68. India Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 69. India Depressive Disorder Market Share by Type (2015-2020)
Table 70. India Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 71. India Depressive Disorder Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Depressive Disorder Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Depressive Disorder Market Share (2019-2020)
Table 74. Central & South America Depressive Disorder Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Depressive Disorder Market Share by Type (2015-2020)
Table 76. Central & South America Depressive Disorder Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Depressive Disorder Market Share by Application (2015-2020)
Table 78. Alkermes Company Details
Table 79. Alkermes Business Overview
Table 80. Alkermes Product
Table 81. Alkermes Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 82. Alkermes Recent Development
Table 83. Allergan Company Details
Table 84. Allergan Business Overview
Table 85. Allergan Product
Table 86. Allergan Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 87. Allergan Recent Development
Table 88. Bristol Myers Squibb Company Details
Table 89. Bristol Myers Squibb Business Overview
Table 90. Bristol Myers Squibb Product
Table 91. Bristol Myers Squibb Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 92. Bristol Myers Squibb Recent Development
Table 93. Eli Lilly Company Details
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Product
Table 96. Eli Lilly Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 97. Eli Lilly Recent Development
Table 98. Glaxosmithkline Company Details
Table 99. Glaxosmithkline Business Overview
Table 100. Glaxosmithkline Product
Table 101. Glaxosmithkline Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 102. Glaxosmithkline Recent Development
Table 103. H. Lundbeck Company Details
Table 104. H. Lundbeck Business Overview
Table 105. H. Lundbeck Product
Table 106. H. Lundbeck Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 107. H. Lundbeck Recent Development
Table 108. Merck Company Details
Table 109. Merck Business Overview
Table 110. Merck Product
Table 111. Merck Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 112. Merck Recent Development
Table 113. Pfizer Business Overview
Table 114. Pfizer Product
Table 115. Pfizer Company Details
Table 116. Pfizer Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 117. Pfizer Recent Development
Table 118. Teva Pharmaceutical Company Details
Table 119. Teva Pharmaceutical Business Overview
Table 120. Teva Pharmaceutical Product
Table 121. Teva Pharmaceutical Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 122. Teva Pharmaceutical Recent Development
Table 123. Takeda Pharmaceutical Company Details
Table 124. Takeda Pharmaceutical Business Overview
Table 125. Takeda Pharmaceutical Product
Table 126. Takeda Pharmaceutical Revenue in Depressive Disorder Business (2015-2020) (Million US$)
Table 127. Takeda Pharmaceutical Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Depressive Disorder Market Share by Type: 2020 VS 2026
Figure 2. Tricyclic Antidepressants Features
Figure 3. Selective Serotonin Reuptake Inhibitors Features
Figure 4. Serotonin-Norepinephrine Reuptake Inhibitors Features
Figure 5. Monoamine Oxidase Inhibitors Features
Figure 6. Serotonin Antagonist And Reuptake Inhibitors Features
Figure 7. Others Features
Figure 8. Global Depressive Disorder Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Diagnostic Centers Case Studies
Figure 12. Homecare Settings Case Studies
Figure 13. Long Term Care Centers Case Studies
Figure 14. Depressive Disorder Report Years Considered
Figure 15. Global Depressive Disorder Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Depressive Disorder Market Share by Regions: 2020 VS 2026
Figure 17. Global Depressive Disorder Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Depressive Disorder Market Share by Players in 2019
Figure 20. Global Top Depressive Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Depressive Disorder as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Depressive Disorder Revenue in 2019
Figure 22. North America Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Depressive Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Bottom-up and Top-down Approaches for This Report
Figure 30. Data Triangulation
Figure 31. Key Executives Interviewed
慢性うつ病性人格障害治療の世界市場（～2026年） Chronic depressive personality disorder also known as Dysthymia is a chronic form of depression. It is mild form of depression which last up to two years or more. This disorder is less severe in comparison to other forms of depression. Symptoms of chronic depressive personality disorder are loss of …- 抗うつ剤の世界市場（～2026年） Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive–compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperact…
- 大うつ病性障害（MDD）の世界市場（～2026年） Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are …
- 産後うつ病治療薬の世界市場（～2026年） Postpartum depression is a prevalent disorder affecting many women of reproductive age. Mood stabilizing medications reduce the risk of postpartum bipolar depression relapse but no randomized controlled trials have examined their use in the acute or prophylactic treatment of postpartum bipolar depre…
- 産後うつ病治療の世界市場（～2026年） Market Analysis and Insights: Global Postpartum Depression Treatment Market The global Postpartum Depression Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Postpartum Depression Treatment Scope and Market Si…